Aclaris Therapeutics, Inc.ACRSNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
13.79%
↑ 45% above average
Average (39q)
9.50%
Historical baseline
Range
High:296.96%
Low:-74.47%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 13.79% |
| Q2 2025 | -1.17% |
| Q1 2025 | 28.34% |
| Q4 2024 | 51.54% |
| Q3 2024 | -32.00% |
| Q2 2024 | -11.03% |
| Q1 2024 | -63.05% |
| Q4 2023 | 11.60% |
| Q3 2023 | -5.54% |
| Q2 2023 | 11.90% |
| Q1 2023 | 7.19% |
| Q4 2022 | -10.92% |
| Q3 2022 | 25.97% |
| Q2 2022 | 31.27% |
| Q1 2022 | 1.45% |
| Q4 2021 | 0.90% |
| Q3 2021 | 76.98% |
| Q2 2021 | 0.75% |
| Q1 2021 | -12.47% |
| Q4 2020 | 43.51% |
| Q3 2020 | -3.50% |
| Q2 2020 | -15.77% |
| Q1 2020 | -33.62% |
| Q4 2019 | -28.54% |
| Q3 2019 | -8.17% |
| Q2 2019 | -11.53% |
| Q1 2019 | 1.96% |
| Q4 2018 | 22.64% |
| Q3 2018 | 13.92% |
| Q2 2018 | 2.78% |
| Q1 2018 | 3.16% |
| Q4 2017 | 21.40% |
| Q3 2017 | 36.40% |
| Q2 2017 | 2.48% |
| Q1 2017 | 11.94% |
| Q4 2016 | -3.06% |
| Q3 2016 | -27.19% |
| Q2 2016 | 3.16% |
| Q1 2016 | 296.96% |
| Q4 2015 | -74.47% |